4.7 Article

LPS-TLR4 signaling to IRF-3/7 and NF-κB involves the toll adapters TRAM and TRIF

Journal

JOURNAL OF EXPERIMENTAL MEDICINE
Volume 198, Issue 7, Pages 1043-1055

Publisher

ROCKEFELLER UNIV PRESS
DOI: 10.1084/jem.20031023

Keywords

innate immunity; endotoxin; interferon; signal transduction; host defense

Funding

  1. NIAID NIH HHS [T32 AI 07349-14, 1R21 AI 0554537 01] Funding Source: Medline
  2. NIDDK NIH HHS [DK 50305, P01 DK050305] Funding Source: Medline
  3. NIGMS NIH HHS [GM 63244, GM 54060, R01 GM054060, R37 GM054060] Funding Source: Medline
  4. Wellcome Trust Funding Source: Medline

Ask authors/readers for more resources

Toll-IL-1-resistance (TIR) domain-containing adaptor-inducing IFN-beta (TRIF)-related adaptor molecule (TRAM) is the fourth TIR domain-containing adaptor protein to be described that participates in Toll receptor signaling. Like TRIF, TRAM activates interferon regulatory factor (IRF)-3, IRF-7, and NF-kappaB-dependent signaling pathways. Toll-like receptor (TLR)3 and 4 activate these pathways to induce IFN-alpha/beta, regulated on activation, normal T cell expressed and secreted (RANTES), and gamma interferon-inducible protein 10 (IP-10) expression independently of the adaptor protein myeloid differentiation factor 88 (MyD88). Dominant negative and siRNA studies performed here demonstrate that TRIF functions downstream of both the TLR3 (dsRNA) and TLR4 (LPS) signaling pathways, whereas the function of TRAM is restricted to the TLR4 pathway. TRAM interacts with TRIF, MyD88 adaptor-like protein (Mal)/TIRAP, and TLR4 but not with TLR3. These studies suggest that TRIF and TRAM both function in LPS-TLR4 signaling to regulate the MyD88-independent pathway during the innate immune response to LPS.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available